1,601
Views
13
CrossRef citations to date
0
Altmetric
REPORT

A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells

, , , , , , , , & show all
Pages 2542-2553 | Received 20 May 2014, Accepted 01 Jun 2014, Published online: 30 Oct 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Song Chen, Michael Haas & Shaogang Sun. (2014) Disrupting the scaffold, an alternative approach to inhibiting FAK . Cell Cycle 13:24, pages 3794-3795.
Read now

Articles from other publishers (12)

Xianbo Wu, Jie Wang, Qi Liang, Rongsheng Tong, Jianli Huang, Xinwei Yang, Yihua Xu, Wenjing Wang, Minghan Sun & Jianyou Shi. (2022) Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment. Biomedicine & Pharmacotherapy 151, pages 113116.
Crossref
Simona D’Aguanno, Fabiana Mallone, Marco Marenco, Donatella Del Bufalo & Antonietta Moramarco. (2021) Hypoxia-dependent drivers of melanoma progression. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Joshua T. Burgess, Emma Bolderson, Mark N. Adams, Pascal H. G. Duijf, Shu-Dong Zhang, Steven G. Gray, Gavin Wright, Derek J. Richard & Kenneth J. O’Byrne. (2020) SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. Scientific Reports 10:1.
Crossref
Connor M. Blair, Nicola M. Walsh, Bruce H. Littman, Frank W. Marcoux & George S. Baillie. (2019) Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf. BMC Cancer 19:1.
Crossref
Ming-Chuan Hsu, Mei-Ren Pan & Wen-Chun Hung. (2019) Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3. Cells 8:3, pages 270.
Crossref
Nassim Khosravi, Heath Skinner & John Heymach. 2018. Molecular Determinants of Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer 469 490 .
Becky H. Lee, Poornima H. Neela, Michael S. Kent & Ashley M. Zehnder. (2017) IQGAP1 is an oncogenic target in canine melanoma. PLOS ONE 12:4, pages e0176370.
Crossref
Jie Shi, Bingyu Guo, Qiang Hui, Peng Chang & Kai Tao. (2017) Fangchinoline suppresses growth and metastasis of melanoma cells by inhibiting the phosphorylation of FAK. Oncology Reports 38:1, pages 63-70.
Crossref
Joshua T. Burgess, Emma Bolderson, Jodi M. Saunus, Shu-Dong Zhang, Lynne E. Reid, Anne Marie McNicol, Sunil R. Lakhani, Katharine Cuff, Kerry Richard, Derek J. Richard & Kenneth J. O’Byrne. (2016) SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer. Oncotarget 7:45, pages 72807-72818.
Crossref
Brittelle E. Kessler, Vibha Sharma, Qiong Zhou, Xia Jing, Laura A. Pike, Anna A. Kerege, Sharon B. Sams & Rebecca E. Schweppe. (2016) FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes. Molecular Cancer Research 14:9, pages 869-882.
Crossref
Sander W. Tas, Chrissta X. Maracle, Emese Balogh & Zoltán Szekanecz. (2015) Targeting of proangiogenic signalling pathways in chronic inflammation. Nature Reviews Rheumatology 12:2, pages 111-122.
Crossref
Katarzyna W. Walkiewicz, Jean-Antoine Girault & Stefan T. Arold. (2015) How to awaken your nanomachines: Site-specific activation of focal adhesion kinases through ligand interactions. Progress in Biophysics and Molecular Biology 119:1, pages 60-71.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.